Periodontitis
Conditions
Keywords
periodontitis, taurine, amnion membrane
Brief summary
45 sites in 15 patients with periodontal pockets ≥ 5mm were selected. These selected sites were divided into 3 groups as Group A, B and C.
Detailed description
Group A (Control): 15 sites received only SRP, Group B: 15 sites received SRP with subgingival placement of amnion membrane, Group C: 15 sites received SRP with subgingival placement of Amnion membrane hydrated with Taurine.
Interventions
PROCEDUREScaling and root planing
15 sites with periodontal pockets ≥ 5mm received only SRP
BIOLOGICALAmnion membrane
15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane.
DRUGTaurine
15 sites with periodontal pockets ≥ 5mm received SRP along with placement of amnion membrane hydrated with taurine.
Sponsors
Maharishi Markendeswar University (Deemed to be University)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
patients and statistician are masked about treatment modality
Intervention model description
Group A (Control): 15 sites received only SRP, Group B: 15 sites received SRP with subgingival placement of amnion membrane, Group C: 15 sites received SRP with subgingival placement of Amnion membrane hydrated with Taurine.
Eligibility
Sex/Gender
ALL
Age
29 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
•Systemically healthy patients with sites showing probing depth (PD) ≥ 5mm, clinical attachment level (CAL) ≥ 4 mm, and vertical bone loss ≥ 3 mm on intraoral periapical radiographs with no history of periodontal therapy or use of antibiotics in the preceding 6 months
Exclusion criteria
* Any systemic disease that could influence the outcome of periodontal therapy. * Smokers, alcoholics & patients with other adverse habits. * Pregnant or nursing women. * Any known allergy or hypersensitivity to any product used in the study. * Patients on long term systemic therapy (antibiotics, anti-inflammatory and any other).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TNF-α level | changes from baseline to 45 days | TNF-α level in Gingival crevicular fluid |
| Probing pocket depth (PPD) | changes from baseline to 45 days | Probing pocket depth at selected site |
| Relative attachment level (RAL) | changes from baseline to 45 days | Relative attachment level from stent to base of the pocket |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque index (PI) | changes from baseline to 45 days | Plaque index (PI) - Silness and Loe 1964 site specific |
| Gingival index (GI) | changes from baseline to 45 days | Gingival index (GI) - Loe and Silness 1963 site specific |
| Bleeding on probing (BOP) | changes from baseline to 45 days | Bleeding on probing (BOP): Muhlemann HR & Son 1971 sit specific |
Countries
India
Outcome results
None listed